Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Evoke Pharma, Inc. (NASDAQ: EVOK).

Full DD Report for EVOK

You must become a subscriber to view this report.


Recent News from (NASDAQ: EVOK)

3 Things In Biotech, August 18: Finally, A New First-Line Treatment For Liver Cancer
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Eisai and Merck's liver cancer partnership pays off Company: Eisai ( OTCPK:ESALY ) and M...
Source: SeekingAlpha
Date: August, 20 2018 11:32
Premarket Gainers as of 9:05 am (08/16/2018)
ANW +43%  on transformative transaction with Mercuria Energy. More news on: Aegean Marine Petroleum Network Inc., Evoke Pharma, Inc., Ferroglobe PLC, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 16 2018 09:11
Evoke Pharma's Gimoti(TM) NDA Accepted for FDA Review
April 1, 2019 PDUFA Target Goal Date Gimoti Brand Name Conditionally Accepted SOLANA BEACH, Calif., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced tha...
Source: GlobeNewswire
Date: August, 16 2018 08:30
Evoke Pharma reports Q2 results
Evoke Pharma (NASDAQ: EVOK ): Q2 EPS of -$0.14 More news on: Evoke Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:39
Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights
Gimoti ™ NDA submitted to FDA on June 1 st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pha...
Source: GlobeNewswire
Date: August, 09 2018 16:05
Evoke Announces FDA Submission of New Drug Application for Gimoti(TM)
SOLANA BEACH, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the submission of its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Adminis...
Source: GlobeNewswire
Date: June, 04 2018 07:30
Evoke Pharma Reports First Quarter 2018 Results and Highlights
NDA submission for Gimoti™ on track for second quarter of 2018 Announced discovery of sex-based pharmacokinetic differences for Gimoti Waiver of the PDUFA fee for Gimoti NDA granted by FDA Cash runway extended into April 2019 SOLANA BEACH, Calif., May 14, 2018 (GLOBE NEWSWIRE)...
Source: GlobeNewswire
Date: May, 14 2018 06:30
Evoke Granted Gender Specific Patent for Gimoti(TM) in Mexico
SOLANA BEACH, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Mexican Institute of Industrial Property has issued a Notice that it intends to gran...
Source: GlobeNewswire
Date: May, 10 2018 07:30
Evoke Granted First Gender Specific Patent for Gimoti(TM)
SOLANA BEACH, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the European Patent Office has issued a Decision to Grant European Union (...
Source: GlobeNewswire
Date: April, 30 2018 07:30
Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments
SOLANA BEACH, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that it has amended the Company’s agreement with Mallinckrodt, ARD Inc. ...
Source: GlobeNewswire
Date: March, 26 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-182.432.372.47262.3630,928
2018-12-172.472.432.4952.4045,885
2018-12-142.512.452.612.4517,625
2018-12-132.572.552.642.4644,834
2018-12-122.632.562.632.5145,030

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-189,06913,57466.8116Short
2018-12-175,45710,30752.9446Short
2018-12-141,2703,51136.1720Short
2018-12-135436,5548.2850Cover
2018-12-127,22112,52257.6665Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EVOK.


About Evoke Pharma, Inc. (NASDAQ: EVOK)

Logo for Evoke Pharma, Inc. (NASDAQ: EVOK)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: EVOK)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: December, 19 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 27 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 18 2018
      Amendment to a previously filed 8-K
      Filing Type: 8-K/AFiling Source: edgar
      Filing Date: April, 06 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 04 2018

       

       


      Daily Technical Chart for (NASDAQ: EVOK)

      Daily Technical Chart for (NASDAQ: EVOK)


      Stay tuned for daily updates and more on (NASDAQ: EVOK)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: EVOK)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EVOK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EVOK and does not buy, sell, or trade any shares of EVOK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/